NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
9.25
-0.37 (-3.85%)
Apr 28, 2026, 4:00 PM EDT - Market closed
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
32.93M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Veru Inc. | 16.89M |
| Palatin Technologies | 8.96M |
| CervoMed | 4.01M |
| Aligos Therapeutics | 2.19M |
| Werewolf Therapeutics | 1.14M |
| RenovoRx | 1.12M |
| Actinium Pharmaceuticals | 90.00K |
NXTC News
- 7 days ago - NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - GlobeNewsWire
- 21 days ago - NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - GlobeNewsWire
- 4 weeks ago - NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - GlobeNewsWire
- 7 weeks ago - NextCure Provides Business Update and Reports Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - NextCure Provides Business Update - GlobeNewsWire
- 5 months ago - NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 5 months ago - NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts - GlobeNewsWire